The Arginine Catabolism-Derived Amino Acid L-Ornithine Is a Chemoattractant for Pseudomonas aeruginosa

Basanta Dhodary 1,†, Inmaculada Sampedro 2,3,4,‡, Shekooh Behroozian 1, Victor Borza 2,‡, Stephanie Her 2 and Jane E. Hill 1,2,*

School of Biomedical Engineering, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; basanta02@hotmail.com (B.D.); shekooh@mail.ubc.ca (S.B.)
Thayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA; isampedro@ugr.es (I.S.); vaborza@gmail.com (V.B.); stephanie.cindy.her@gmail.com (S.H.)
Biomedical Research Center (CIBM), Biotechnology Institute, Avda del Conocimiento s/n, 18100 Armilla, Spain
Department of Microbiology, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071 Granada, Spain
* Correspondence: jane.hill@ubc.ca
† These authors contributed equally to this work.

Abstract: Pseudomonas aeruginosa is a common, opportunistic bacterial pathogen among patients with cystic fibrosis, asthma, and chronic obstructive pulmonary disease. During the course of these diseases, L-ornithine, a non-proteinogenic amino acid, becomes more abundant. P. aeruginosa is chemotactic towards other proteinogenic amino acids. Here, we evaluated the chemotaxis response of P. aeruginosa towards L-ornithine. Our results show that L-ornithine serves as a chemoattractant for several strains of P. aeruginosa, including clinical isolates, and that the chemoreceptors involved in P. aeruginosa PAO1 are PctA and PctB. It seems likely that P. aeruginosa’s chemotactic response to L-ornithine might be a common feature and thus could potentially contribute to pathogenesis processes during colonization and infection scenarios.

Keywords: chemotaxis; L-ornithine; Pseudomonas aeruginosa; chemoreceptor

1. Introduction

Pseudomonas aeruginosa (Pa) is a widely occurring Gram-negative bacterial pathogen which can cause a variety of opportunistic infections in humans worldwide [1–3]. For example, Pa is the leading cause of nosocomial infections in immunocompromised, cystic fibrosis (CF), cancer and burn patients [1,4–8]. Pa is known to be naturally resistant to many antimicrobial agents making its eradication increasingly challenging [9].

The success of a bacterial infection relies, in part, on organism’s management of and adaptation to the host environment. One mechanism utilized by some bacteria is an ability to move towards or away from chemical gradients using their chemosensing and motility apparatuses which may increase their access to desired substances or avoid hostile environments [10,11]. Several studies have revealed that chemotaxis behaviors play an important role in Pa infections [12,13]. Pa strain PAO1 (PAO1) and by analogy, other strains of Pa, has 26 putative methyl-accepting chemotaxis proteins (MCPs) that feed into four chemosensory pathways (Che, Che2, Chp, Wsp) [13]. The MCPs linked to chemosensing of the 20 natural, proteinogenic L-amino acids, are PctA, PctB, and PctC [14,15].

Arginine is one of the most versatile amino acids in human body [16]. Arginine is the precursor to L-ornithine, polyamines, proline, agmatine, and creatinine. Arginine is converted to L-ornithine in the presence of arginase [16–18]. Heightened production of arginase in persons with CF, asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension and idiopathic pulmonary fibrosis is thought to lead to the presence of more L-ornithine in lung environment [19]. L-ornithine is also known to...
promote Pa biofilm formation in vitro [20]. We hypothesize that L-ornithine serves as a chemoattractant to the opportunistic pathogen Pa.

2. Materials and Methods

2.1. Bacterial Strains and Culture Conditions

The strains used in this study are listed in Table 1 and Supplementary Table S1. PAO1 and the 24 MCP single mutants of PAO1 were obtained from Dr. Junichi Kato (Hiroshima University, Japan). The clinical isolates of Pa from acute infections and one environmental strain were kindly provided by Dr. Joseph D. Schwartzman and Dr. Michael Zegans (Geisel School of Medicine, Dartmouth College). Prior to being used in chemotaxis assays, all strains were incubated overnight at 37 °C in minimal salts medium (MSB) [21] supplemented with 0.5% (w/v) casamino acids (Amresco, Solon, OH, USA) and 27.5 mM glucose.

Table 1. Bacterial Strains and plasmids.

| Strain or Plasmid | Characteristics | Reference or Source |
|-------------------|-----------------|---------------------|
| **Pseudomonas aeruginosa PAO1** | Prototroph, FP (sex factor minus) | [22] |
| PCT2 | PAO1 derivative, ΔpctC, ΔpctA, Δorfl, ΔpctB::Km | [14] |
| PCTA1 | PAO1 derivative, ΔpctA::Km | [23] |
| PCTB1 | PAO1 derivative, ΔpctB::Km | [14] |
| PCTC1 | PAO1 derivative, ΔpctC::Km | [14] |
| PCT2pMAI18-1(pctA) | PAO1 derivative, ΔpctB, ΔpctC::Cb | This study |
| PCT2pMAI18-1(pctB) | PAO1 derivative, ΔpctA, ΔpctC::Cb | This study |
| PCT2pMAI18-1(pctC) | PAO1 derivative, ΔpctA, ΔpctB::Cb | This study |
| P. aeruginosa 577 | Clinical isolate from peritoneal fluid | PA8 § |
| P. aeruginosa 581 | Clinical isolate from toe | PA1 § |
| P. aeruginosa 590 | Clinical isolate from leg | PA2 § |
| P. aeruginosa 627 | Clinical isolate from trachea | PA42 § |
| P. aeruginosa 738 | Clinical isolate from eye | [24] |
| P. aeruginosa 595 | Clinical isolate from throat | PA6 § |
| P. aeruginosa 617 | Clinical isolate from abdominal fluid | PA36 § |
| P. aeruginosa MSH3 | Environmental strain | [25] |
| **Plasmids** | | |
| pUCP18 | Broad-host-range cloning vector; Cb | [26] |
| pMAI18-1 | pUCP18 with pctA(2.1 kb), Cb | [27] |
| pMAI18-2 | pUCP18 with pctB(2.1 kb); Cb | [27] |
| pMAI18-3 | pUCP18 with pctC(2.1 kb), Cb | [27] |

Km, kanamycin; Cb, carbenicillin. § Culture collections obtained from Dr. Schwartzman (Geisel School of Medicine, Dartmouth).

2.2. DNA Manipulation and Electroporation

Standard procedures were followed for the manipulation of plasmid DNA as described previously [28]. To generate PCT2 pMAI18-1(pctA), PCT2 pMAI18-1(pctB), and PCT2 pMAI18-1(pctC), PCT2 was transformed by electroporation [29] with the vector pMAI18-1 (carrying pctA), pMAI18-2 (carrying pctB), and pMAI18-3 (carrying pctC) [27], respectively.

2.3. L-ornithine Purity Analysis

We checked the purity of L-ornithine used for chemotaxis assays by LC/MS/MS analysis (without chemical derivatization) on a Waters Quattro micro-mass spectrometer coupled to Shimadzu high performance liquid chromatography (HPLC), as described previously [30]. The purity analysis of L-ornithine with HPLC revealed that it has low percentage (0.1%) of arginine contamination. Statistical analysis clearly shows that PAO1 chemotaxis response to L-ornithine is not the consequence of arginine contamination (ANOVA test (p ≤ 0.05), p = 0.034).
2.4. Chemotaxis Assays

Three \textit{L}-ornithine, \textit{L}-arginine, and casamino acids used for the study were obtained from Amresco (Solon, OH, USA) at the highest purity commercially available. All the test compounds for chemotaxis assays were prepared in chemotaxis buffer (CB) containing 50 mM sodium phosphate buffer (pH 7.0), 10 mM disodium EDTA and 0.05% (w/v) glycerol.

The qualitative capillary assays were carried out as described previously [31,32]. Briefly, bacterial cells were harvested in mid-exponential phase ($OD_{660}$ 0.3–0.4) by centrifugation at 4600 revolutions per min (rpm) for 5 min and washed once with CB. Washed cells were suspended in CB and diluted to $OD_{660}$ 0.1 and then placed in a chemotaxis chamber formed by a coverslip and a glass U-tube. Microcapillaries (1 $\mu$L) were filled with 10 mM of each test compounds in a gel of 2% (w/v) low-melting-temperature agarose (Nusieve GTG; Lonza, Switzerland) in CB and inserted into the pool of bacterial cells. The amino acids \textit{L}-ornithine and \textit{L}-arginine were tested at 0.001, 0.01, 0.1, 1 and 10 mM. In all experiments, negative controls (CB) and positive controls (0.2%, w/v, casamino acids) were included. The responses were visualized at 0 and 5 min via an Olympus IX73 inverted microscope with an Olympus TH4-100 halogen illuminator and photographed using an Olympus DP73 CCD camera with Olympus cellSens standard version 1.8 software. The dark-field illumination was generated using a Ph2 ring in the long-working distance condenser NA 0.55 with a UPlanFLN 4X NA. 0.13 objective. Images were processed (contrast and brightness) as well as centered using Adobe Photoshop Lightroom. The data were normalized by subtracting the response seen at 0 min from response seen at 5 min using the Matlab R2013a program to obtain a heat map of bacterial chemotactic responses. Two independent replicates and two technical repeats of assays were performed per test samples.

Quantitative capillary assays were carried out as described previously [31,33]. Briefly, bacterial cells were harvested in mid-exponential phase ($OD_{660}$ 0.3–0.4) by centrifugation (4600 rpm) for 5 min and washed once with CB. Cells were then resuspended and diluted to an $OD_{660}$ of 0.1. The capillary tubes consisted of 1$\mu$L disposable micropipettes with one end sealed via flame and filled with the chemoattractant resuspended in CB. After incubation in the pool of cells for 30 min at room temperature, the capillary was removed, the exterior was rinsed with sterile chemotaxis buffer, and the contents of the capillaries were transferred to tubes of CB via centrifugation (8000 rpm). Dilution in CB and then plating allowed for determination of the number of colony forming units per capillary (CFUs/capillary). The amino acids \textit{L}-ornithine and \textit{L}-arginine were tested at 0.001, 0.01, 0.1, 1 and 10 mM. In all experiments, negative controls (CB) and positive controls (0.2%, w/v, casamino acids) were used. Data are represented as the mean $\pm$ SEM of at least four independent experiments with two technical replicates each. The results have been normalized with CB.

3. Results

3.1. \textit{PAO1} Chemotaxis towards \textit{L}-ornithine

We evaluated the chemotaxis potential of \textit{PAO1} and \textit{L}-ornithine using standard qualitative (Figure 1a) and quantitative (Figure 1b) capillary chemotaxis assays. \textit{PAO1} cells formed clearly visible clouds of turbidity because of their accumulation around the open end of capillaries containing 0.1, 1 and 10 mM ornithine (Figure 1a and Supplementary Figure S1). The observations were further confirmed by quantitative assays carried out in the same range of ornithine concentrations (Figure 1b). We observed the maximum chemotaxis response at 1 mM concentration. The chemotaxis response of \textit{PAO1} to arginine was included for direct comparison (Figure 1b).
Figure 1. Capillary chemotaxis assays of PAO1 towards different L-ornithine concentrations. (a) Dark-field images of cells gathered at the mouth of capillaries containing attractants. All photographs were taken after 5 min. A normalization of the response visualized at 5 min with respect to the time 0 min for each treatment is represented with a jet Colormap (MATLAB R2013b version 8.2) in Supplementary Figure S1. (b) Quantitative chemotaxis response of PAO1 towards different L-ornithine and L-arginine concentrations. Results are averages of at least 12 capillaries from five independent experiments; the results have been normalized with CB as the negative control; error bars indicate standard errors, *p < 0.05 (by Tukey’s test).

3.2. L-Ornithine Chemotaxis Is Mediated by PctA and PctB Receptors in PAO1

Chemotaxis receptors PctA, PctB, and PctC mediate chemotaxis towards proteinogenic amino acids, some non-proteinogenic amino acids, and some intermediates of amino acids metabolism for PAO1 [14,15]. L-ornithine is a non-proteinogenic amino acid derived from metabolism of arginine, thus, we hypothesized that it might serve as an attractant for PAO1, mediated by some or all of these three receptors. In order to identify the chemoreceptors involved in L-ornithine chemotaxis, we screened mutants in the presence of 1mM L-ornithine in which single chemoreceptor genes (pctA, pctB, pctC), and all three chemoreceptor genes (triple mutant with all three pctA, pctB, and pctC) had been deleted (Table 1). The PctABC triple mutant (PCT2) almost completely abolished chemoattraction towards L-ornithine compared to the wild-type strain (Figure 2). The single mutant strains PctA and PctB also showed strongly reduced chemoattraction to L-ornithine (Figure 2), indicating the involvement of both chemoreceptors in L-ornithine chemotaxis for PAO1. The chemoreceptors PctA, PctB, and PctC were reconstituted in the PctABC triple mutant strain to effectively generate double knockout mutants PctBC, PctAC, and PctAB, respectively. The quantitative capillary assays of PctAC and PctBC mutant strains to L-ornithine resulted in significant chemotaxis, whereas PctAB abolished chemotaxis (Figure 2). This confirms that mutation in both PctA and PctB receptors are necessary to completely abolish chemotaxis of PAO1 towards L-ornithine. Additionally, to rule out the involvement of other receptors, we performed qualitative capillary assays with other 21 MCP single mutants (Supplementary Table S1). All MCP mutants showed chemotaxis response to L-ornithine at 1 mM (Supplementary Figure S2), suggesting that these receptors are not involved in L-ornithine chemotaxis.
to rule out the involvement of other receptors, we performed qualitative capillary assays with other 21 MCP single mutants (Supplementary Table S1). All MCP mutants showed chemotaxis response to L-ornithine at 1 mM (Supplementary Figure S2), suggesting that these receptors are not involved in L-ornithine chemotaxis.

Figure 2. Capillary chemotaxis assays of wild-type PAO1, its mutant PAO1 ΔpctA (PctA), PAO1 ΔpctB (PctB), PAO1 ΔpctC (PctC), PAO1 ΔpctABC (PctABC), PAO1 ΔpctAB (PctAB), PAO1 ΔpctAC (PctAC) and PAO1 ΔpctBC (PctBC) towards 1 mM L-ornithine. (a) Dark-field images of cells gathered at the mouth of capillaries containing attractants. All photographs were taken after 5 min. A normalization of the response visualized at 5 min with respect to the time 0 min for each treatment is represented with a jet Colormap (MATLAB R2013b version 8.2) in Supplementary Figure S3. Chemotaxis buffer (CB) and casamino acids (CA) were used as negative and positive control, respectively. (b) Quantitative comparison of L-ornithine chemotaxis response between the wild-type strain and its mutants indicated by Dunn’s test (*p < 0.05). The graph shows CFU in capillaries normalized by the negative control (CB). Results are averages of at least four independent experiments; error bars indicate standard errors.

3.3. Diverse Pa Isolates Are Attracted to L-ornithine

To evaluate if this phenomenon of L-ornithine chemotaxis might be generalizable to other Pa strains, we conducted qualitative chemotaxis assays on diverse eight, motile Pa strains (seven clinical isolates and one environmental strain) (Table 1). These clinical strains were isolated from patients with acute peritoneal fluid, toe, leg, trachea, eye, abdominal fluid and throat infections. Three strains, originating from peritoneal fluid, toe and abdominal fluid infections, exhibited putative chemotaxis to L-ornithine (Figure 3).
Previous studies suggest that Pct chemoreceptors are associated with *Pa* virulence. For example, PctB-mediated chemotaxis to glutamine [14,15], the most abundant amino acid in human cells [37], potentially relates to virulence, and this receptor might be especially valuable for efficient host colonization by *Pa* [38]. In addition, a PctABC triple mutant was reported to be less efficient in colonizing wounds of human CF airway epithelial cells [39]. Furthermore, PctA and PctB protein levels are downregulated in *Pa* isolated...
from the sputum of patients with CF [40]. Therefore, taken together, our work adds to the growing suggestion that amino acid chemotaxis is likely primarily important for the initial stages of bacterial attachment and infection in humans and animals, where amino acid concentrations, including L-ornithine [41], in sputum or lung are high, especially in patients with CF [42]. Further studies are required to evaluate precise and specific roles of amino acid chemotaxis on the fate and activity of Pa in human and animal infections.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/microorganisms10020264/s1; Figure S1. Normalized jet Colormap of qualitative capillary chemotaxis responses of wild-type PAO1 towards different concentrations of ornithine (mM). A normalization of the response visualized at 5 min respect to the time 0 min for each treatment is represented with a jet Colormap (MATLAB R2013b version 8.2). Figure S2. Qualitative capillary chemotaxis assays of 21 MCP mutants of PAO1 towards ornithine (1 mM). Dark-field images of cells gathered at the mouth of capillaries containing ornithine (first, third and fifth columns). All photographs were taken after 5 min. A normalization of the response visualized at 5 min with respect to the time 0 min for each treatment is represented with a jet Colormap (MATLAB R2013b version 8.2) (second, fourth and sixth column). Figure S3. Normalized jet Colormap of qualitative capillary chemotaxis responses of wild-type PAO1, its mutant *P. aeruginosa* PAO1 ΔpctA (PctA), PAO1 ΔpctB (PctB), PAO1 ΔpctC (PctC), PAO1 ΔpctABC (PctABC), PAO1 ΔpctAB (PctAB), PAO1 ΔpctAC (PctAC) and PAO1 ΔpctBC (PctBC) towards 1 mM L-ornithine. A normalization of the response visualized at 5 min with respect to the time 0 min for each treatment is representing with a jet Colormap (MATLAB R2013b version 8.2). Chemotaxis buffer (CB) and casamino acids (CA) were used as negative and positive control, respectively. Figure S4. Normalized jet Colormap of qualitative capillary chemotaxis responses of PAO1 and other *Pa* strains (seven clinical isolates and one environmental strain) to 1 mM L-ornithine. A normalization of the response visualized at 5 min with respect to the time 0 min for each treatment is represented with a jet Colormap (MATLAB R2013b version 8.2). Table S1. *P. aeruginosa* PAO1 strain and MCP single mutants of PAO1.

**Author Contributions:** Conceptualization, I.S. and J.E.H.; methodology, I.S., V.B. and S.H.; data analysis, I.S., J.E.H. and B.D.; writing, B.D., J.E.H. and S.B.; funding acquisition, J.E.H. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded, in part, by the United States Cystic Fibrosis Foundation (Hill16I0).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data are presented in the paper and the supporting information. Original data files will be available upon request from the authors.

**Acknowledgments:** We are grateful to Junichi Kato from Hiroshima University, Japan for providing PAO1 and the 24 MCP single mutants of PAO1. We thank Joseph D. Schwartzman and Michael Zegans from the Geisel School of Medicine, Dartmouth, USA, for providing clinical isolates as well as an environmental strain of *Pa*. We thank Michigan State University Mass Spectrometry Core for performing HPLC analysis. We thank Sara M. Hashmi and Saeed Alborzi for guiding us to generate jet Colormap using MATLAB.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Gellatly, S.L.; Hancock, R.E. *Pseudomonas aeruginosa*: New insights into pathogenesis and host defenses. *Pathog. Dis.* 2013, 67, 159–173. [CrossRef] [PubMed]
2. Silby, M.W.; Winstanley, C.; Godfrey, S.A.; Levy, S.B.; Jackson, R.W. *Pseudomonas* genomes: Diverse and adaptable. *FEMS Microbiol. Rev.* 2011, 35, 652–680. [CrossRef] [PubMed]
3. Moradali, M.F.; Ghods, S.; Rehm, B.H. *Pseudomonas aeruginosa* lifestyle: A paradigm for adaptation, survival, and persistence. *Front. Cell Infect. Microbiol.* 2017, 7, 39. [CrossRef] [PubMed]
4. Juhas, M. *Pseudomonas aeruginosa* essentials: An update on investigation of essential genes. *Microbiology* 2015, 161, 2053–2060. [CrossRef]
5. Lyczak, J.B.; Cannon, C.L.; Pier, G.B. Establishment of *Pseudomonas aeruginosa* infection: Lessons from a versatile opportunist. *Microbes Infect.* 2000, 2, 1051–1060. [CrossRef]
6. Malhotra, S.; Hayes, D., Jr.; Wozniak, D.J. Cystic fibrosis and Pseudomonas aeruginosa: The host-microbe interface. Clin. Microbiol. Rev. 2019, 32, e00138-18. [CrossRef]

7. Rossi, E.; La Rosa, R.; Bartell, J.A.; Marvig, R.L.; Haagensen, J.A.; Sommer, L.M.; Molin, S.; Johansen, H.K. Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis. Nat. Rev. Microbiol. 2021, 19, 331–342. [CrossRef]

8. Faure, E.; Kwong, K.; Nguyen, D. Pseudomonas aeruginosa in chronic lung infections: How to adapt within the host? Front. Immunol. 2018, 9, 2416. [CrossRef]

9. Pang, Z.; Raudonis, R.; Glick, B.R.; Lin, T.J.; Cheng, Z. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies. Biotechnol. Adv. 2019, 37, 177–192. [CrossRef]

10. Sampedro, I.; Parales, R.E.; Krell, T.; Hill, J.E. Pseudomonas chemotaxis. FEMS Microbiol. Rev. 2015, 39, 17–46. [CrossRef]

11. Ortega, A.; Zhulin, I.B.; Krell, T. Sensory repertoire of bacterial chemoreceptors. Microbiol. Mol. Biol. Rev. 2017, 81, e00033-17. [CrossRef] [PubMed]

12. Matilla, M.A.; Krell, T. The effect of bacterial chemotaxis on host infection and pathogenicity. FEMS Microbiol. Rev. 2018, 42, fux052. [CrossRef] [PubMed]

13. Matilla, M.A.; Martín-Mora, D.; Gavira, J.A.; Krell, T. Pseudomonas aeruginosa as a Model to Study Chemosensory Pathway Signaling. Microbiol. Mol. Biol. Rev. 2021, 85, e01520-20. [CrossRef] [PubMed]

14. Taguchi, K.; Fukutomii, H.; Kuroda, A.; Kato, J.; Ohtake, H. Genetic identification of chemotactic transducers for amino acids in Pseudomonas aeruginosa. Microbiology 1997, 143, 3223–3229. [CrossRef] [PubMed]

15. Rico-Jiménez, M.; Muñoz-Martínez, F.; García-Fontana, C.; Fernandez, M.; Morel, B.; Ortega, A.; Ramos, J.L.; Krell, T. Paralogous chemoreceptors mediate chemotaxis towards protein amino acids and the non-protein amino acid gamma-aminobutyrate (GABA). Mol. Microbiol. 2013, 88, 1230–1243. [CrossRef]

16. Wu, G.; Morris, S.M., Jr. Arginine metabolism: Nitric oxide and beyond. Biochem. J. 1998, 336, 1–17. [CrossRef]

17. Scibior, D.; Czeczot, H. Arginine-metabolism and functions in the human organism. Postepy Hig. Med. Dosw. 2004, 58, 321–332.

18. Morris, S.M., Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu. Rev. Nutr. 2002, 22, 87–105. [CrossRef]

19. Maarsingh, H.; Pera, T.; Meurs, H. Arginase and pulmonary diseases. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2008, 378, 171. [CrossRef]

20. Bernier, S.P.; Ha, D.G.; Khan, W.; Merritt, J.H.; O’Toole, G.A. Modulation of surface-associated group behaviors by individual amino acids through e-di-GMP signaling. Res. Microbiol. 2011, 162, 680–688. [CrossRef]

21. Stanier, R.Y.; Palleroni, N.J.; Doudoroff, M. The aerobic pseudomonads a taxonomic study. Microbiology 1966, 43, 159–271. [CrossRef] [PubMed]

22. Holloway, B.; Krishnapillai, V.; Morgan, A. Chromosomal genetics of Pseudomonas. Microbiol. Rev. 1979, 43, 73–102. [CrossRef] [PubMed]

23. Kuroda, A.; Kumano, T.; Taguchi, K.; Nikata, T.; Kato, J.; Ohtake, H. Molecular cloning and characterization of a chemotactic transducer gene in Pseudomonas aeruginosa. J. Bacteriol. 1995, 177, 7019–7025. [CrossRef] [PubMed]

24. Zegans, M.E.; Wozniak, D.; Griffin, E.; Toutain-Kidd, C.M.; Hammond, J.H.; Garfoot, A.; Lam, J.S. Pseudomonas aeruginosa exopolysaccharide Psl promotes resistance to the biofilm inhibitor polysorbate 80. Antimicrob. Agents Chemother. 2012, 56, 4112–4122. [CrossRef] [PubMed]

25. Wolfgang, M.C.; Kulasekara, B.R.; Liang, X.; Boyd, D.; Wu, K.; Yang, Q.; Miyada, C.G.; Lory, S. Conservation of genome content and virulence determinants among clinical and environmental isolates of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. USA 2003, 100, 8484–8489. [CrossRef] [PubMed]

26. Schweizer, H. Escherichia-Pseudomonas shuttle vectors derived from pUC18/19. Gene 1991, 97, 109–112. [CrossRef]

27. Shitashiro, M.; Tanaka, H.; Soo Hong, C.; Kuroda, A.; Takiguchi, N.; Ohtake, H.; Kato, J. Identification of chemosensory proteins for trichloroethylene in Pseudomonas aeruginosa. J. Biosci. Bioeng. 2005, 99, 396–402. [CrossRef]

28. Ausubel, F.B.R.; Kingston, R.E.; Moore, D.D.; Setdman, J.G.; Smith, J.A.; Struhl, K. Current Protocols in Molecular Biology. Part 1: E. coli, Plasmids, and Bacteriophages; Wiley: New York, NY, USA, 1993.

29. Masduki, A.; Nakamura, J.; Ogha, T.; Umezaki, R.; Kato, J.; Ohtake, H. Isolation and characterization of chemotaxis mutants and genes of Pseudomonas aeruginosa. J. Bacteriol. 1995, 177, 948–952. [CrossRef]

30. Gu, L.; Jones, A.D.; Last, R.L. Rapid LC–MS/MS profiling of protein amino acids and metabolically related compounds for large-scale assessment of metabolic phenotypes. In Amino Acid Analysis. Methods in Molecular Biology; Humana Press: Totowa, NJ, USA, 2012; Volume 828, pp. 1–11. [CrossRef]

31. Sampedro, I.; Kato, J.; Hill, J.E. Elastin degradation product isodesmosine is a chemoattractant for Pseudomonas aeruginosa. Microbiology 2015, 161, 1496–1503. [CrossRef]

32. Parales, R.E.; Ditty, J.L.; Harwood, C.S. Toluene-degrading bacteria are chemotactic towards the environmental pollutants benzene, toluene, and trichloroethylene. Appl. Environ. Microbiol. 2000, 66, 4098–4104. [CrossRef] [PubMed]

33. Adler, J. A method for measuring chemotaxis and use of the method to determine optimum conditions for chemotaxis by Escherichia coli. Microbiol. 1973, 74, 77–91. [CrossRef] [PubMed]

34. Jeong, H.H.; Lee, S.H.; Kim, J.M.; Kim, H.E.; Kim, Y.G.; Yoo, J.Y.; Chang, W.S.; Lee, C.S. Microfluidic monitoring of Pseudomonas aeruginosa chemotaxis under the continuous chemical gradient. Biosens. Bioelectron. 2010, 26, 351–356. [CrossRef] [PubMed]
35. Lacal, J.; Alfonso, C.; Liu, X.; Parales, R.E.; Morel, B.; Conejero-Lara, F.; Rivas, G.; Duque, E.; Ramos, J.L.; Krell, T. Identification of a chemoreceptor for tricarboxylic acid cycle intermediates: Differential chemotactic response towards receptor ligands. J. Biol. Chem. 2010, 285, 23126. [CrossRef] [PubMed]

36. Martín-Mora, D.; Reyes-Darias, J.A.; Ortega, A.; Corral-Lugo, A.; Matilla, M.A.; Krell, T. McpQ is a specific citrate chemoreceptor that responds preferentially to citrate/metal ion complexes. Environ. Microbiol. 2016, 18, 3284–3295. [CrossRef] [PubMed]

37. Brosnan, J.T. Interorgan amino acid transport and its regulation. J. Nutr. 2003, 133, 2068S–2072S. [CrossRef]

38. Gavira, J.A.; Gumerov, V.M.; Rico-Jiménez, M.; Petukh, M.; Upadhyay, A.A.; Ortega, A.; Matilla, M.A.; Zhulin, I.B.; Krell, T. How bacterial chemoreceptors evolve novel ligand specificities. Mbio 2020, 11, e03066-19. [CrossRef]

39. Schwarzer, C.; Fischer, H.; Machen, T.E. Chemotaxis and binding of Pseudomonas aeruginosa to scratch-wounded human cystic fibrosis airway epithelial cells. PLoS ONE 2016, 11, e0150109. [CrossRef]

40. Kamath, K.S.; Pascovici, D.; Penesyan, A.; Goel, A.; Venkatakrishnan, V.; Paulsen, I.T.; Packer, N.H.; Molloy, M.P. Pseudomonas aeruginosa cell membrane protein expression from phenotypically diverse cystic fibrosis isolates demonstrates host-specific adaptations. J. Proteome Res. 2016, 15, 2152–2163. [CrossRef]

41. Mehl, A.; Ghorbani, P.; Douda, D.; Huang, H.; Palaniyar, N.; Ratjen, F.; Grasemann, H. Effect of arginase inhibition on pulmonary L-arginine metabolism in murine Pseudomonas pneumonia. PLoS ONE 2014, 9, e90232. [CrossRef]

42. Thomas, S.R.; Ray, A.; Hodson, M.E.; Pitt, T.L. Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease. Thorax 2000, 55, 795–797. [CrossRef] [PubMed]